ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1446

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

Klaus Krüger 1, Gerd Burmester 2, Siegfried Wassenberg 3, Astrid Thiele 4 and Matthias Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Charité—University Medicine Berlin, Berlin, Germany, 3Centre of Rheumatology, Ratingen, Germany, 4Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 5MSD Sharp & Dohme GmbH, Haar, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, Golimumab, rheumatoid athirtis and spondylarthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in RA, PsA and AS in a real-life setting.

Methods: Post hoc analysis of the non-interventional, GO-NICE study with RA, PsA and AS patients starting GLM 50mg SC in a real practice setting in Germany, details were shown earlier (1,2). Endpoint measures DAS28, PsARC, and BASDAI are shown as observed.

Results: In 1458 patients with RA, PsA or AS, GLM was administered as first (n=305, 286, 292, respectively), second (n=104, 136, 130), or at least third biologic agent (n=64, 79, 58). In total, 43.0, 30.8, 39.1% of patients with RA, 53.1, 38.2, 34.2% with PsA, and 53.8, 49.2, 41.4% with AS completed the study until month 24. RA pts. (n=473): Baseline DAS28 scores were 5.0, 4.9, 5.1 in 1st, 2nd, and at least 3rd line use of GLM, respectively, and dropped significantly over time in all groups. Remission rates increased to 27.5%, 19.5%, and 14.5% (month 3) to 45.3%, 50.0% and 33.3% after 24 months of treatment, respectively. PsA pts. (n=501): PsARC response was achieved in 76.4%, 51.0% and 50.0% respectively in patients with GLM use as 1st, 2nd, at least 3rd line at 24 months. AS pts. (n=483): Patients with at least 2 previous bDMARDs had higher BASDAI at BL than patients with GLM use in first or second line: 5.7 vs. 5.0, and 4.9. After 24 months of treatment, the mean BASDAI scores decreased significantly (p< 0.001 vs. BL) to 2.1, 2.9, 2.9 in 1st, 2nd, and at least 3rd line use of GLM, respectively.

Conclusion: In this post-hoc analysis of the non-interventional study, Golimumab as first, second or at least third biologic agent were an effective treatment and showed remarkable improvements in clinical parameters DAS28, PsARC, and BASDAI in patients with RA, PsA, and AS.
Significant improvements of DAS28 and BADSAI was arrived after 3 months vs. BL and maintained over 24 months.


ACR Abstract 123_Table

Table: Effectiveness parameters at BL vs month 24 with GLM use as 1st, 2nd, at least 3rd line


Disclosure: K. Krüger, AbbVie, 5, 8, Biogen, 5, 8, BMS, 5, 8, Celgen, 8, Celgene, 5, 8, Hexal, 5, 8, Janssen, 5, 8, Lilly, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi, 5, 8, Sanofi-Aventis, 5, UCB, 5, 8; G. Burmester, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma., 5, 8, AbbVie Inc., 5, 8, BMS, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Merck Shar & Dohme, 5, 8, MSD, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche, Sanofi-Genzyme, 5, 8, Sanofi, 5, 8, UCB, 5, 8, Union Chimique Belge, 2, 5, 8; S. Wassenberg, AbbVie, 5, 8, Chugai, 5, 8, Janssen, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8; A. Thiele, Biogen, 8, Celgen, 8, Chugai, 8, Hexal, 8, Janssen, 8, Lilly, 8, MSD, 8, Novartis, 8, Pfizer, 8, UCB, 8; M. Thomas, MSD Shap & Dohme GmbH Germany, 3, MSD Sharp & Dohme GmbH, Germany, 3.

To cite this abstract in AMA style:

Krüger K, Burmester G, Wassenberg S, Thiele A, Thomas M. Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/golimumab-as-first-second-or-at-least-third-biologic-agent-in-patients-with-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-or-ankylosing-spondylitis-as-post-hoc-analysis-of-a-non-in/. Accessed January 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/golimumab-as-first-second-or-at-least-third-biologic-agent-in-patients-with-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-or-ankylosing-spondylitis-as-post-hoc-analysis-of-a-non-in/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.